Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study

BACKGROUND: The U.S. Food and Drug Administration (FDA) often approves new drugs based on trials that use surrogate markers for endpoints, which involve certain trade-offs and may risk making erroneous inferences about the medical product’s actual clinical effect. This study aims to compare the trea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Med
Hlavní autoři: Wallach, Joshua D., Ciani, Oriana, Pease, Alison M., Gonsalves, Gregg S., Krumholz, Harlan M., Taylor, Rod S., Ross, Joseph S.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2018
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5863466/
https://ncbi.nlm.nih.gov/pubmed/29562926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-018-1023-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky